AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportRecursion Pharmaceuticals vs BenevolentAI
Recursion Pharmaceuticals
VS
BenevolentAI
Verdict by Category
Detailed category analysis is not available for this comparison.
Detailed Comparison
Feature
Recursion Pharmaceuticals
BenevolentAI
Pricing
CustomRecursion operates through three revenue streams: pharma collaboration agreements, data licensing, and its own internal drug pipeline.
Pharma partnerships (Roche/Genentech, Sanofi) are structured as multi-year agreements with upfront payments and milestone-based payments tied to program progress. Recursion has earned $500M+ in cumulative milestones to date, with $134M from Sanofi alone.
Data licensing allows external researchers and pharma companies to access Recursion's proprietary biology maps and phenomics datasets for their own target discovery programs.
Recursion's own clinical programs (REC-4881, REC-1245, REC-4539) will generate revenue through future partnering, co-development, or commercialization deals as they advance through clinical trials. Total 2025 revenue: $74.7M. Contact Recursion through recursion.com for partnership inquiries.
CustomBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing.
Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development.
Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
AI-native drug discovery OS with industrial-scale automated labs and $500M+ in pharma partnerships
Clinical-stage AI drug discovery with integrated wet labs and AstraZeneca and Merck collaborations
Recursion Pharmaceuticals Pros & Cons
Pros
- $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
- Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
- Industrial-scale automated labs generate data no other company can replicate
- Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
- Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
- Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
- Cash runway guided into early 2028 — disciplined capital allocation
Cons
- Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
- Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
- Acquired Exscientia in 2024 — integration complexity and added operational overhead
- No approved drugs yet — clinical proof of concept still early stage
- Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
BenevolentAI Pros & Cons
Pros
- Fully integrated AI + wet lab model — unique among AI drug discovery platforms
- AstraZeneca and Merck partnerships validate the platform's target identification quality
- In-house wet labs in Cambridge close the loop between AI prediction and biology
- Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
- Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
- Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
- Knowledge exploration tools can be licensed separately from drug pipeline
Cons
- Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
- Clinical pipeline still in early stages — no approved drugs yet
- Smaller than competitors like Recursion in terms of funding and team size
- Revenue dependent on collaboration milestones — lumpy and uncertain
- Wet-lab operations add cost complexity vs. pure software drug discovery peers